No Data
AIM Vaccine Submits Application for Clinical Trial of Rabies Vaccine to Chinese Regulator
Express News | Application for Clinical Trial of Aim Vaccine’s Human Diploid Rabies Vaccine
Aimei vaccine (06660.HK): The iterative process efficiently produces a recombinant human diploid rabies vaccine, applying for clinical trials.
Gelonghui November 7th | AIMM vaccine (06660.HK) announced that the group's developed iterative process efficient human diploid rabies vaccine has recently been submitted for clinical review to the China Food and Drug Administration's Drug Evaluation Center (CDE). Rabies is the disease with the highest fatality rate in the world. Once infected, the fatality rate is close to 100%. Currently, there is no effective treatment for rabies in clinical practice, so prevention after exposure is crucial. The main preventative measure is to administer human rabies vaccines. There are two types of rabies vaccines: one with serum and one without serum, but currently there is no serum-free rabies vaccine available.
AIM Vaccine Gets Marketing Approval From China's NMPA After Phase III Trials Completion
Sino Biopharmaceutical (06660) has obtained the corresponding production license for 13-valent pneumococcal conjugate vaccine, submitted for market registration, and the bottom transaction has hit a historic new high.
According to the Securities Times app, Amy Vaccine (06660) announced that the company's independently developed 13-valent combined pneumonia vaccine has been submitted to the National Pharmaceuticals and Food and Drug Administration...
Express News | AIM Vaccine - Unit Obtained Requisite Drug Production License From Nmpa for Manufacturing 13-Valent Pneumonia Conjugate Vaccine
AIM Vaccine Insider Ups Holding By 649% During Year
No Data
No Data
